ATP2A1 and Brody myopathy: Equally we might speculate that benefits may occur in clinical populations such as Brody disease (where SERCA1 activity is significantly reduced; Guglielmi et al. 2013) or Duchenne Muscular Dystrophy (where an excess of cytosol Ca2+occurs; Ohlendieck 2000).